Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 487-491, November 2006

Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma☆

Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31–June 3, 2003

Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA

Received 22 September 2005; received in revised form 16 March 2006; accepted 17 March 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This work was supported by Roche Laboratories, Inc., Nutley, NJ, and NCI core grant No. CA16672.

PII: S1078-1439(06)00091-3

doi:10.1016/j.urolonc.2006.03.004

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 487-491, November 2006

Article Tools